SEPN
Septerna Inc · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -16.7% ·
share flow -30.0% ·
net new positions -20.0%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Millennium Management ✦ | 436.56K | New | $2.53M | 0.0% | New | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 409.64K | +7.6% | $2.37M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 3 | State Street Global Advisors ✦ (passive) | 344.60K | +26.3% | $2.00M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Two Sigma Investments ✦ | 74.84K | New | $433,329 | 0.0% | New | 1 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 22.96K | -95.6% | $133,000 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Millennium Management | $2.53M | 0.0% |
| Two Sigma Investments | $433,329 | 0.0% |
Exited
| Citadel Advisors | $9.27M | was 0.0% |
| Adage Capital Partners | $6.87M | was 0.0% |
| Soros Fund Management | $229,000 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 123 holders, 45.64M shares, $1.09B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director, 10% owner · 746.50K sh · $31.73M
Director, 10% owner · 746.50K sh · $31.73M
10% owner · 147.06K sh · $7.39M
10% owner · 141 sh · $7,202
Officer · 25.00K sh · $1.10M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
11.8% of class · View original SEC filing ↗